Research article
Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis
-
* Corresponding author: Dario Neri dario.neri@pharma.ethz.ch
1 Philochem AG, c/o ETH Zurich, Institute of Pharmaceutical Sciences, Wolfgang-Pauli-Strasse 10 HCI E520, CH-8093 Zurich, Switzerland
2 Institute of Pharmaceutical Sciences, ETH Zürich, Wolfgang-Pauli-Strasse 10, CH-8093 Zurich, Switzerland
3 Centro Interdipartimentale Studio Biochimico-Clinico Patologie Osteoarticolari, Via Doninzetti 7, University of Siena, 53100 Siena, Italy
4 Department of Rheumatology, Instituto Ortopedico Gaetano Pini, via Pini 9, 20122 Milan, Italy
Arthritis Research & Therapy 2009, 11:R142 doi:10.1186/ar2814
Published: 25 September 2009Additional files
Additional file 1:
A Figure showing crossreactivity of F8-IL10 study on tissue microarray sections (Biochain, Hayward, USA). Sections were blocked with FCS and then incubated with 5 μg/ml of purified FITC-labeled F8-IL10 for one hour. For amplification of the signal bound antibody was detected using rabbit anti-FITC antibody and subsequent AlexaFluor594 goat anti-rabbit IgG. Slides were mounted with glycergel and analyzed with an AxioScop 2MOT+ fluorescence microscope. None of the healthy tissue sections showed any staining with F8-IL10, except for ovary (1/3), placenta (3/3) and uterus (2/3).
Format: PDF Size: 3.2MB Download file
This file can be viewed with: Adobe Acrobat Reader
